Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01830855 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,596
- Enrollment target
NCT01830855 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 3,596 participants.
The verdict
NCT01830855, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,596 participants
- Enrollment target
Study Summary
This study is looking at a new vaccine that might prevent meningococcal disease, and will study whether healthy adolescent subjects receiving different lots of vaccine respond in a similar way. The study will also look at the safety of the new vaccine as well as how it is tolerated.
Interventions
- BIOLOGICAL Saline
- BIOLOGICAL rLP2086
- BIOLOGICAL Havrix (HAV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,596 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01830855
The ClinicalTrials.gov registry entry for NCT01830855 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,596 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT01830855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01830855 about?
NCT01830855 is a clinical study titled "A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years". This study is looking at a new vaccine that might prevent meningococcal disease, and will study whether healthy adolescent subjects receiving different lots of vaccine respond in a similar way. The study will also look at the safety of the new vaccine as well as how it is tolerated.
What is the current status of trial NCT01830855?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,596 participants. The study started on 2013-04. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01830855?
The interventions under investigation include: Saline (BIOLOGICAL), rLP2086 (BIOLOGICAL), Havrix (HAV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01830855?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.